SENSITITRE HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC SUSCEPTIBILITY PLATES
K013925 · Trek Diagnostic Systems, Inc. · JWY · Dec 21, 2001 · Microbiology
Device Facts
| Record ID | K013925 |
| Device Name | SENSITITRE HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC SUSCEPTIBILITY PLATES |
| Applicant | Trek Diagnostic Systems, Inc. |
| Product Code | JWY · Microbiology |
| Decision Date | Dec 21, 2001 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.1640 |
| Device Class | Class 2 |
Intended Use
The Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Streptococcus pneumoniae and Haemophilus influenzae. This 510(k) is for the addition of Meropenem in the dilution range of 0.016 - 2 ug/ml to the Sensititre Haemophilus/Streptococcus pneumoniae MIC panel for testing Streptococcus pneumoniae and Haemophilus influenzac isolates. The "Indications for Use" and clinical significance of Meropenem is for: Streptococcus pneumoniae (excluding penicillin-resistant strains)
Device Story
Sensititre HP MIC Susceptibility Plates are in vitro diagnostic tools used in clinical laboratories to determine the Minimum Inhibitory Concentration (MIC) of antibiotics against specific bacteria. This submission adds Meropenem (0.016–2 µg/mL) to existing panels. The device consists of microtiter plates containing dehydrated antimicrobial agents. Laboratory technicians inoculate the plates with patient bacterial isolates; plates are incubated to allow bacterial growth. The device provides a quantitative MIC result, which helps clinicians select appropriate antibiotic therapy for patients with Streptococcus pneumoniae or Haemophilus influenzae infections. The system facilitates standardized susceptibility testing, aiding in the management of bacterial infections.
Clinical Evidence
No clinical data provided; substantial equivalence is based on performance characteristics of the antimicrobial susceptibility test system.
Technological Characteristics
Microtiter plate format containing dehydrated antimicrobial agents (Meropenem). Standardized broth microdilution method for MIC determination. In vitro diagnostic device for laboratory use.
Indications for Use
Indicated for clinical susceptibility testing of Streptococcus pneumoniae (excluding penicillin-resistant strains) and Haemophilus influenzae isolates using Meropenem.
Regulatory Classification
Identification
An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.
Related Devices
- K021627 — SENSITITRE HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC PLATE · Trek Diagnostic Systems, Inc. · Jun 20, 2002
- K021339 — HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE · Trek Diagnostic Systems, Inc. · May 9, 2002
- K062816 — SENSITITRE HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC PLATE · Trek Diagnostic Systems, Inc. · Nov 1, 2006
- K062839 — MODIFICATION TO SENSITITRE HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC PLATE · Trek Diagnostic Systems, Inc. · Nov 9, 2006
- K062722 — SENSITITRE HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC PLATE · Trek Diagnostic Systems, Inc. · Oct 20, 2006
Submission Summary (Full Text)
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular pattern around the symbol. The caduceus symbol is black, and the text is also black. The logo is simple and recognizable, and it is used to represent the U.S. Department of Health & Human Services.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
DEC 2 1 2001
Ms. Cynthia C. Knapp Director of Lab Services Trek Diagnostic Systems, Inc. 29299 Clemens Road, Suite 1-K Westlake, OH 44145
k013925 Re:
Trade/Device Name: Sensititre™ Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility Plates, Meropenem Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Powder Regulatory Class: Class II Product Code: JWY Dated: November 13, 2001 Received: November 14, 2001
Dear Ms. Knapp:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket I ntis lotter will and hype ding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, (Jory of the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## 510 (k) Number (If known): Kol 3925
Device Name: Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility Plates.
Indications For Use:
The Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Streptococcus pneumoniae and Haemophilus influenzae.
This 510(k) is for the addition of Meropenem in the dilution range of 0.016 - 2 ug/ml to the Sensititre Haemophilus/Streptococcus pneumoniae MIC panel for testing Streptococcus pneumoniae and Haemophilus influenzac isolates. The "Indications for Use" and clinical significance of Meropenem is for: Streptococcus pneumoniae (excluding penicillin-resistant strains)
## (PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| | Woody Dechoes |
|---------------|-----------------------------------------|
| | (Division Sign/Off) |
| | Division of Clinical Laboratory Devices |
| 510(k) Number | K013925 |
| Prescription Use<br>(Per 21 CFR 801.109 | <div style="text-align:center;">X</div> | OR | Over-The-Counter Use |
|-----------------------------------------|-----------------------------------------|----|----------------------|
|-----------------------------------------|-----------------------------------------|----|----------------------|